The Twin4Pharma initiative, led by the Research Center Pharmaceutical Engineering (RCPE), is driving the digital and green transformation in pharmaceutical development. With 18 partners from academia and industry, this € 3.75 million COMET Module addresses long-standing inefficiencies in drug development, where only one in 10,000 candidates reaches the market after an average of 12 years, with costs exceeding € 2-3 billion.
By integrating advanced digital technologies such as AI-driven modeling and predictive analytics, Twin4Pharma accelerates development, reduces experimental costs, and strengthens supply chain resilience. This leads to a more viable and sustainable pharmaceutical production in Europe.
Innovating Computationally-Driven Processes for Small Molecules and Biologics
Twin4Pharma introduces computational process optimization to improve efficiency and sustainability in small molecule and biologic drug manufacturing:
Small Molecules
- Flow chemistry, purification, and crystallization benefit from advanced simulations and predictive modeling.
- These innovations reduce reliance on empirical testing, accelerate development timelines, and enhance scalability and consistency.
Biologics
- Optimized freeze-thaw cycles minimize risks related to protein denaturation and aggregation.
- Computational modeling ensures higher stability and efficacy in biologic therapies, ultimately improving patient outcomes.
In addition, a holistic digital platform will be set up in the project, in which the results obtained (e.g. models and automated workflows) will be made available. This is intended to ensure transferability to other pharmaceutical engineering use cases.
By integrating cutting-edge computational tools, Twin4Pharma enhances efficiency, reliability, and sustainability in pharmaceutical development, setting new benchmarks for digitally enabled and environmentally responsible drug manufacturing.
Learn more: rcpe.at/twin4pharma
